Our Science
Reading the brain through the blood
Niki BioSolutions, through its wholly owned subsidiary DiamiR Biosciences, is developing a new generation of minimally invasive diagnostic tests that detect and monitor brain health conditions and other diseases from a simple blood draw. Our approach is founded on a straightforward biological insight: the organs of the body, including the brain, continuously release small regulatory RNA molecules into the bloodstream, and the pattern of those molecules changes when the organ is affected by disease. By measuring the right molecules with precision, it is possible to assess what is happening inside the brain without imaging, lumbar puncture, or surgery.
Technology at a Glance
DiamiR started as a microRNA platform company in 2012. Today, our laboratory provides genomic and biomarker testing services, including APOE genotyping, to research organizations and biopharmaceutical partners.
The biology of circulating microRNAs
MicroRNAs are short, non-coding RNA molecules of roughly 19 to 23 nucleotides that regulate gene expression after transcription. A single microRNA can modulate dozens of target genes, and many microRNAs are expressed preferentially in specific organs, specific brain regions, or specific cellular compartments such as synapses and neurites. When cells are stressed, damaged, or lost, their microRNAs are released into the extracellular space and cross into the circulation, where they remain remarkably stable. Unlike cell-free DNA, which is often scarce in plasma when the source tissue sits behind the blood-brain barrier, circulating microRNAs are abundant, diverse, and readily measured by quantitative PCR.
Because synaptic dysfunction and neuronal loss begin years before clinical symptoms in many neurological conditions, the microRNAs shed during these processes offer a window into disease at its earliest, most treatable stages. They also respond dynamically to changes in disease activity, which makes them well suited to tracking progression and measuring the effect of treatment.
Therapeutic Development
- Neuroblastoma – SCAT-1 small molecule
- Treatment of MRSA & Staph A – ALS-4 small molecule
From research to clinical use
Our tests are developed first as laboratory-developed tests for use in clinical research and drug development, where they help sponsors identify eligible participants, stratify patient populations, and measure treatment response objectively. As clinical validation matures, we intend to bring these tests into broader clinical practice to support earlier diagnosis, more informed planning of care, and more effective use of emerging disease-modifying therapies.
To ensure the rigor of this work, we partner with specialist organizations at each stage of development. Bioinformatics and biostatistical analysis across the Alzheimer’s program is supported by Fios Genomics, an independent provider of high-throughput data analysis to the pharmaceutical and biotechnology sectors. Our clinical studies are conducted with leading academic medical centers, and our programs are supported by disease foundations and federal research agencies.
The platform
Our proprietary platform is built on the targeted, quantitative analysis of organ-enriched microRNAs in blood plasma. Rather than surveying the entire microRNA transcriptome, we pre-select panels of microRNAs on the basis of their enrichment in the organ or brain region of interest, their presence in synapses, and their association with inflammation and other disease-relevant pathways. This targeted design yields assays that are biologically interpretable, analytically robust, and practical to run at scale.
Three features distinguish the platform:
Organ-enriched selection
Each panel is constructed from microRNAs known to be concentrated in the tissue affected by the disease under study. For Alzheimer’s disease, this means microRNAs enriched in the hippocampus and cortex; for Rett syndrome, microRNAs from the brain as well as the liver, lung, and muscle, all of which are affected by the disorder; for glioblastoma, microRNAs implicated in tumor-promoting and tumor-suppressive pathways.
Pairwise ratio normalization
MicroRNA levels are analyzed as ratios between pairs of molecules rather than as absolute concentrations. This internal normalization cancels out technical variability and systematic effects, such as changes in blood supply or blood-brain barrier permeability, that would otherwise confound interpretation. It also allows microRNAs from unaffected regions to serve as built-in reference points.
Classifier algorithms
Proprietary software evaluates all possible microRNA pair ratios, identifies those with the strongest discriminatory performance, and combines them into multi-biomarker classifiers that output a probability score. This approach has consistently produced classifiers with high sensitivity and specificity across neurodegenerative, neurodevelopmental, and oncologic indications.
The platform is protected by more than 50 issued patents worldwide, spanning the use of organ-enriched microRNAs for screening, differential diagnosis, patient stratification, and monitoring of disease progression and treatment response.
Our laboratory
All testing is performed in DiamiR’s CLIA-certified, CAP-accredited clinical laboratory in New Haven, Connecticut. The laboratory operates validated workflows for plasma RNA extraction and quantitative RT-PCR, and has published analytical validation data demonstrating that its microRNA measurements are robust, reproducible, and consistent across runs. In addition to microRNA assays, the laboratory offers protein and genetic biomarker analyses, including plasma-based APOE genotyping, which allows us to combine complementary biomarker classes within a single sample and a single workflow.
Pipeline
DiamiR's microRNA platform is expanding from brain health into rare disease and neuro-oncology
- APOE genotyping Progress: 100%
- CogniMIR® (Alzheimer's risk) Progress: 72%
- Rett syndrome test Progress: 43%
- Glioblastoma blood test Progress: 43%
- Long-COVID Progress: 26%
- Neuroblastoma Progress: 100%
- Treatment of MRSA & Staph A Progress: 100%
Programs
APOE Genotyping Services
Apolipoprotein E (APOE) genotyping for clinical and translational research is performed in our CAP-accredited and New York State-permitted laboratory. APOE genotype is a key genetic marker with clinical significance in Alzheimer's disease, cardiovascular health, and lipid metabolism research, and is increasingly relevant to eligibility and safety monitoring in Alzheimer's disease therapeutic programs.
View programCogniMIR®
Our lead test candidate has completed analytical validation and is undergoing clinical validation for risk stratification and early detection of mild cognitive impairment and Alzheimer's disease. Earlier-stage programs apply the same approach to glioblastoma, neurodevelopmental disorders, and screening for other organ pathologies.
View programGlioblastoma
This program is investigating the utility of plasma microRNA signatures as minimally invasive biomarkers of glioblastoma, in collaboration with the University of Pennsylvania. Glioblastoma carries a median survival of fewer than 15 months after diagnosis, and its detection and monitoring rely on imaging and invasive biopsy. A blood-based marker could support earlier detection and monitoring.
View programRett Syndrome
Brain-enriched microRNAs are also being studied as biomarkers in neurodevelopmental disorders, including Rett syndrome for prognosticating disease severity. Because the degree of change in specific microRNA signatures tracks with clinical severity scores and disease progression, the test offers a minimally invasive, objective way to gauge how severely a patient is affected and to monitor response to treatment over time.
View programPublications
Analytical Validation of a Novel MicroRNA Panel for Risk Stratification of Cognitive Impairment (opens in a new tab)
Evaluation of long-term COVID-19 (opens in a new tab)
Brain-enriched microRNAs circulating in plasma as novel biomarkers for Rett syndrome (opens in a new tab)
Aging and aging-associated diseases: a microRNA-based endocrine regulation hypothesis (opens in a new tab)
Age- and sex-dependent changes in levels of circulating brain-enriched microRNAs during normal aging (opens in a new tab)
Circulating brain-enriched microRNAs as novel biomarkers for detection and differentiation of neurodegenerative diseases (opens in a new tab)
Universal screening test based on analysis of circulating organ-enriched microRNAs: a novel approach to diagnostic screening (opens in a new tab)
Analysis of organ-enriched microRNAs in plasma as an approach to development of Universal Screening Test: feasibility study (opens in a new tab)
Plasma microRNA biomarkers for detection of mild cognitive impairment: biomarker validation study (opens in a new tab)
Circulating cell-free microRNA as biomarkers for screening, diagnosis, and monitoring of neurodegenerative diseases and other neurologic pathologies (opens in a new tab)
Early detection of neurodegenerative diseases: Circulating brain-enriched microRNA. (opens in a new tab)
mCiRNA—Synaptic Crystal Ball? (opens in a new tab)
Plasma microRNA biomarkers for detection of mild cognitive impairment. (opens in a new tab)
No publications match your search.
Collaborate with us
Niki BioSolutions works with academic investigators, disease foundations, and biopharmaceutical companies seeking blood-based biomarkers for brain health and other indications. We welcome inquiries regarding research collaborations, clinical trial support, and access to our laboratory services.